Literature DB >> 21725802

MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?

Alessandro Della Puppa1, Luca Persano, Giulia Masi, Elena Rampazzo, Alessandro Sinigaglia, Francesca Pistollato, Luca Denaro, Luisa Barzon, Giorgio Palù, Giuseppe Basso, Renato Scienza, Domenico d'Avella.   

Abstract

We recently described a three-layer concentric model of a glioblastoma (GBM) related to a specific distribution of molecular and phenotypic characteristics driven by the intratumoral hypoxic gradient in which the cancer stem cells niche is located in the hypoxic necrotic core of the tumour. The purpose of this study was to investigate the relationship between O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and MGMT expression in GBM samples collected according to the three-layer concentric model. Multiple tissue samples were obtained, by means of image-guided surgery, from the three concentric layers of newly diagnosed GBM. Two samples from each layer were collected from 12 patients (total 72 samples). Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded tissue samples. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. In all tumours, MGMT protein expression decreased progressively from the inner to the outer layer, and methylation of the MGMT promoter was unrelated to tumour layer. In particular, the MGMT promoter was unmethylated in all layers in 41.7% of tumours, methylated in all layers in 25%, and variably methylated in the three layers in 33.3%. We recorded concordance between MGMT expression and MGMT promoter methylation status within the GBM in only 58.8% of the samples collected. Our data suggest that both MGMT expression and promoter methylation data may be variable throughout GBM and that they may, consequently, depend on the site of surgical sample collection, even in the same patient. However, whereas MGMT expression is pre-operatively predictable when sampling is performed according to the three-layer concentric model, MGMT promoter methylation is not. These results must be considered when sample collection is performed for assessment of MGMT data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725802     DOI: 10.1007/s11060-011-0639-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

Review 1.  MGMT: its role in cancer aetiology and cancer therapeutics.

Authors:  Stanton L Gerson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy: a preliminary study of ten patients.

Authors:  Corrado Iaccarino; Davide Nicoli; Carmine Gallo; Davide Nasi; Anna Pisanello; Gianni De Berti; Reza Ghadirpour; Norina Marcello; Franco Servadei
Journal:  Acta Neurochir (Wien)       Date:  2010-03-31       Impact factor: 2.216

3.  O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.

Authors:  Carme Balaña; Jose Luis Ramirez; Miquel Taron; Yannis Roussos; Aurelio Ariza; Rosa Ballester; Carme Sarries; Pedro Mendez; Jose Javier Sanchez; Rafael Rosell
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

Review 4.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors:  Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal:  Nat Rev Neurol       Date:  2009-12-08       Impact factor: 42.937

5.  Predicting lung cancer by detecting aberrant promoter methylation in sputum.

Authors:  W A Palmisano; K K Divine; G Saccomanno; F D Gilliland; S B Baylin; J G Herman; S A Belinsky
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

6.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Authors:  K A van Nifterik; J van den Berg; W F van der Meide; N Ameziane; L E Wedekind; R D M Steenbergen; S Leenstra; M V M Lafleur; B J Slotman; L J A Stalpers; P Sminia
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

7.  Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

Authors:  Matthias Preusser; Robert Charles Janzer; Jörg Felsberg; Guido Reifenberger; Marie-France Hamou; Annie-Claire Diserens; Roger Stupp; Thierry Gorlia; Christine Marosi; Harald Heinzl; Johannes A Hainfellner; Monika Hegi
Journal:  Brain Pathol       Date:  2008-04-08       Impact factor: 6.508

8.  Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Authors:  Sibille Everhard; Jörg Tost; Hafida El Abdalaoui; Emmanuelle Crinière; Florence Busato; Yannick Marie; Ivo G Gut; Marc Sanson; Karima Mokhtari; Florence Laigle-Donadey; Khê Hoang-Xuan; Jean-Yves Delattre; Joëlle Thillet
Journal:  Neuro Oncol       Date:  2009-02-17       Impact factor: 12.300

9.  Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.

Authors:  Tetsuji Nakagawachi; Hidenobu Soejima; Takeshi Urano; Wei Zhao; Ken Higashimoto; Yuji Satoh; Shiroh Matsukura; Shinichi Kudo; Yoshihiko Kitajima; Haruhito Harada; Koichi Furukawa; Hideki Matsuzaki; Mitsuru Emi; Yusaku Nakabeppu; Kohji Miyazaki; Mutsuo Sekiguchi; Tsunehiro Mukai
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

10.  MGMT immunohistochemical expression and promoter methylation in human glioblastoma.

Authors:  Fausto J Rodriguez; Stephen N Thibodeau; Robert B Jenkins; Karen V Schowalter; Bolette L Caron; Brian P O'neill; Charles David James; Charles David James; Sandra Passe; Jeff Slezak; Caterina Giannini
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-01
View more
  13 in total

1.  Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.

Authors:  Vera C Keil; Bogdan Pintea; Gerrit H Gielen; Susanne Greschus; Rolf Fimmers; Jürgen Gieseke; Matthias Simon; Hans H Schild; Dariusch R Hadizadeh
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

Review 2.  MGMT testing allows for personalised therapy in the temozolomide era.

Authors:  A Dullea; L Marignol
Journal:  Tumour Biol       Date:  2015-10-30

3.  MGMT promoter methylation in plasma of glioma patients receiving temozolomide.

Authors:  Valentina Fiano; Morena Trevisan; Elisa Trevisan; Rebecca Senetta; Anna Castiglione; Carlotta Sacerdote; Anna Gillio-Tos; Laura De Marco; Chiara Grasso; Michela Magistrello; Fabrizio Tondat; Roberta Rudà; Paola Cassoni; Riccardo Soffietti; Franco Merletti
Journal:  J Neurooncol       Date:  2014-02-12       Impact factor: 4.130

4.  MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.

Authors:  H J Choi; S H Choi; S-H You; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn; C-K Park; S-H Park
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

Review 5.  Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Authors:  Giulio Cabrini; Enrica Fabbri; Cristiana Lo Nigro; Maria Cristina Dechecchi; Roberto Gambari
Journal:  Int J Oncol       Date:  2015-05-29       Impact factor: 5.650

Review 6.  Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.

Authors:  Junfeng Zhang; Heng Liu; Haipeng Tong; Sumei Wang; Yizeng Yang; Gang Liu; Weiguo Zhang
Journal:  Contrast Media Mol Imaging       Date:  2017-03-20       Impact factor: 3.161

7.  Rapid Screen of Potential i-Motif Forming Sequences in DNA Repair Gene Promoters.

Authors:  R Aaron Rogers; Aaron M Fleming; Cynthia J Burrows
Journal:  ACS Omega       Date:  2018-08-21

8.  BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.

Authors:  L Persano; F Pistollato; E Rampazzo; A Della Puppa; S Abbadi; C Frasson; F Volpin; S Indraccolo; R Scienza; G Basso
Journal:  Cell Death Dis       Date:  2012-10-18       Impact factor: 8.469

Review 9.  Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.

Authors:  Niklas Thon; Simone Kreth; Friedrich-Wilhelm Kreth
Journal:  Onco Targets Ther       Date:  2013-09-27       Impact factor: 4.147

10.  MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.

Authors:  Dong Shen; Tao Liu; Qingfen Lin; Xiangdong Lu; Qiong Wang; Feng Lin; Weidong Mao
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.